moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
Company profile
Ticker
MBRX
Exchange
Website
CEO
Walter V. Klemp
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Moleculin Australia • Moleculin Amsterdam B.V. ...
MBRX stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
18 Apr 24
8-K
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
10 Apr 24
8-K
Other Events
8 Apr 24
8-K
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
27 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 24
8-K
Moleculin Reports Full Year 2023 Financial Results
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
20 Mar 24
8-K
Moleculin Announces Reverse Stock Split
19 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.58 mm | 24.58 mm | 24.58 mm | 24.58 mm | 24.58 mm | 24.58 mm |
Cash burn (monthly) | 2.53 mm | 2.15 mm | 1.98 mm | 2.31 mm | 2.52 mm | 2.16 mm |
Cash used (since last report) | 17.33 mm | 14.73 mm | 13.57 mm | 15.84 mm | 17.23 mm | 14.81 mm |
Cash remaining | 7.25 mm | 9.85 mm | 11.01 mm | 8.74 mm | 7.35 mm | 9.77 mm |
Runway (months of cash) | 2.9 | 4.6 | 5.6 | 3.8 | 2.9 | 4.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.43 bn |
Total shares | 8.87 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lincoln Park Capital Fund | 4.79 mm | $122.36 mm |
CVI Investments | 1.80 mm | $59.30 mm |
Vanguard | 1.08 mm | $625.18 mm |
Sio Capital Management | 303.39 k | $175.60 mm |
Geode Capital Management | 246.45 k | $142.65 mm |
BLK Blackrock | 196.20 k | $113.56 mm |
Renaissance Technologies | 127.40 k | $74.00 k |
Squarepoint Ops | 77.24 k | $44.71 mm |
STT State Street | 71.40 k | $41.33 mm |
NTRS Northern Trust | 53.60 k | $31.02 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Dec 23 | Klemp Walter V | Common Stock | Buy | Acquire P | No | No | 0.69 | 188,404 | 130.00 k | 680,880 |
26 Dec 23 | Foster Jonathan P. | Common Stock | Buy | Acquire P | No | No | 0.69 | 28,986 | 20.00 k | 80,556 |
26 Dec 23 | George Robert E. | Common Stock | Buy | Acquire P | No | No | 0.69 | 14,493 | 10.00 k | 14,660 |
11 Jul 23 | Klemp Walter V | Common Stock | Payment of exercise | Dispose F | No | No | 0.5903 | 3,216 | 1.90 k | 492,476 |
11 Jul 23 | Klemp Walter V | Common Stock | Option exercise | Acquire M | No | No | 0 | 13,204 | 0.00 | 495,692 |
11 Jul 23 | Klemp Walter V | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 13,204 | 0.00 | 1,928,145 |
22 Jun 23 | Picker Donald H | RSU Common Stock | Grant | Acquire A | No | No | 0 | 105,938 | 0.00 | 437,948 |
22 Jun 23 | Picker Donald H | Stock option Common Stock | Grant | Acquire A | No | No | 0.6 | 100,000 | 60.00 k | 332,010 |
News
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $40 Price Target
12 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Maxim Group Maintains Buy on Moleculin Biotech, Lowers Price Target to $20
26 Mar 24
Moleculin Biotech Provided A Preliminary Update On Recent Clinical Activity And Expected Near Term Milestones For Its Lead Program MB-106 For The Treatment Of Acute Myeloid Leukemia
25 Mar 24
Moleculin Biotech FY23 EPS $(15.07) Vs $(15.22) YoY; As Of December 31, 2023, The Company Had Cash And Cash Equivalents Of $23.6M
22 Mar 24
Press releases
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
18 Apr 24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
10 Apr 24
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
27 Mar 24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 24